In this exploratory study of omega-3 in patients with hyperlipidemia receiving HMG-CoA reductase inhibitors, there was no improvement (measured as an increase) in fasting  %FMD after 8 weeks of treatment at either 2 g or 4 g. The gene discussed is HMGCR; the disease is hyperlipidemia.